Sponsor
Jules Bordet Institute
Clinical research sponsor
Clinical trials
60 shownLUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.NCT07370597 · lead sponsor · 2026-02-01
RECRUITINGStereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)NCT06925984 · lead sponsor · 2025-10-30
RECRUITINGKetorolac and Pregabalin Effects on breaSt Cancer (KePreSt)NCT06150898 · lead sponsor · 2025-05-12
RECRUITINGSalvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.NCT06523634 · lead sponsor · 2024-12-10
RECRUITINGThe Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)NCT06867588 · lead sponsor · 2024-10-17
RECRUITINGMolecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint InhibitorsNCT06107608 · lead sponsor · 2023-06-13
RECRUITINGMultidisciplinary Approach to FatigueNCT05502224 · lead sponsor · 2022-08-19
RECRUITINGPSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer.NCT06059469 · lead sponsor · 2022-05-30
RECRUITINGAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.NCT02102165 · lead sponsor · 2014-04-01
RECRUITINGMedical Imaging to Re-evaluate Elacestrant Clinical UsageNCT07753954 · lead sponsor · 2026-09-13
NOT_YET_RECRUITINGHER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerNCT06595563 · lead sponsor · 2026-06-30
TERMINATEDPregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCANCT07591532 · lead sponsor · 2026-06-01
NOT_YET_RECRUITINGEvaluation of the RESTART Survival ProgrammeNCT06283511 · lead sponsor · 2025-03-01
NOT_YET_RECRUITINGICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing StudyNCT06227338 · lead sponsor · 2024-02-12
UNKNOWNPROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)NCT05880446 · lead sponsor · 2023-10-06
COMPLETEDImmunological Variables Associated to ICI Toxicity in Cancer PatientsNCT05429866 · lead sponsor · 2022-09-01
UNKNOWNDe-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeNCT04675827 · lead sponsor · 2022-01-17
TERMINATEDCOVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2NCT05075538 · lead sponsor · 2021-12-01
TERMINATEDEvaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerNCT04856475 · lead sponsor · 2021-11-24
WITHDRAWNProCaLung: Project on Cancer of the LungNCT04726358 · lead sponsor · 2021-10-01
UNKNOWNMicro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINENCT04831905 · lead sponsor · 2021-03-01
UNKNOWNNeoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)NCT04551495 · lead sponsor · 2021-01-14
UNKNOWNNeo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:NCT03875573 · lead sponsor · 2019-11-06
ACTIVE_NOT_RECRUITINGPaclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCNCT03616886 · lead sponsor · 2018-12-28
ACTIVE_NOT_RECRUITINGKadcyla In pAtients With bRAin MetastasisNCT03203616 · lead sponsor · 2018-02-23
WITHDRAWNNeoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)NCT03065621 · lead sponsor · 2017-07-05
COMPLETEDSafety of Pregnancy in BRCA Mutated Breast Cancer PatientsNCT03673306 · lead sponsor · 2017-01-16
COMPLETEDProspective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient ManagementNCT02810886 · lead sponsor · 2016-10-01
WITHDRAWNDouble-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide ConsumptionNCT02655965 · lead sponsor · 2016-05-01
COMPLETEDBiomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncerNCT02338531 · lead sponsor · 2015-06-01
WITHDRAWNTRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free RegimenNCT02053597 · lead sponsor · 2014-10-01
WITHDRAWNPet Imaging as a Biomarker in Hormone Refractory postmenopausaL WomenNCT02028364 · lead sponsor · 2014-01-12
COMPLETEDStudy of the ICG Distribution in the Margins of Breast Cancer After TumorectomyNCT02027818 · lead sponsor · 2014-01-01
COMPLETEDThe Jules Bordet Institute Molecular Profiling Program Feasibility TrialNCT01932489 · lead sponsor · 2013-12-01
COMPLETEDStudy of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant TherapyNCT02032563 · lead sponsor · 2013-12-01
UNKNOWNPhase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast CancersNCT01843725 · lead sponsor · 2013-09-01
COMPLETEDEvaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLCNCT01913067 · lead sponsor · 2013-09-01
WITHDRAWNA Study to Evaluate Denosumab in Young Patients With Primary Breast CancerNCT01864798 · lead sponsor · 2013-07-01
TERMINATEDEvaluation of Two Techniques for the SLN Detection in BC PatientsNCT02032498 · lead sponsor · 2013-07-01
UNKNOWNBIG Molecular Screening Feasibility StudyNCT02094742 · lead sponsor · 2013-05-01
COMPLETEDICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.NCT01993576 · lead sponsor · 2013-01-01
COMPLETEDEffectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile NeutropeniaNCT01658956 · lead sponsor · 2012-07-01
UNKNOWNHER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1NCT01565200 · lead sponsor · 2012-05-01
COMPLETEDTrial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast CancerNCT01537536 · lead sponsor · 2011-11-01
COMPLETEDPilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer PatientsNCT01420146 · lead sponsor · 2011-08-01
COMPLETEDEarly Cardiac Toxicity of Adjuvant CT in Elderly BC.NCT01301040 · lead sponsor · 2011-03-01
TERMINATEDLate Cardiac Evaluation of the Three Arm Belgian Trial Involving Node-positive Early Breast Cancer PatientsNCT01554943 · lead sponsor · 2010-07-01
COMPLETEDGenomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast CancerNCT01916837 · lead sponsor · 2010-02-01
COMPLETEDLapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast CancerNCT00614978 · lead sponsor · 2008-01-01
COMPLETEDMagnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast CancerNCT00398437 · lead sponsor · 2006-09-01
UNKNOWNFRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to LetrozoleNCT00199134 · lead sponsor · 2004-11-01
COMPLETEDPS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2NCT00199212 · lead sponsor · 2003-10-01
COMPLETEDAdjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II StudyNCT00263705 · lead sponsor · 2003-01-01
COMPLETEDTopoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of EpirubicinNCT00162812 · lead sponsor · 2003-01-01
TERMINATEDPhase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICINCT04954599 · collaborator · 2023-05-30
RECRUITINGA Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 InhibitorsNCT06171360 · collaborator · 2022-11-15
RECRUITINGThe MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyNCT04075305 · collaborator · 2019-02-01
RECRUITINGAntibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.NCT07294430 · collaborator · 2026-12-31
NOT_YET_RECRUITINGDisease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy AnalysesNCT07635654 · collaborator · 2026-07-01
NOT_YET_RECRUITINGClinical, Histological and In-depth Molecular Characterization as Well as Experimental Models of Liver Metastasis From Patients With Breast Cancer in Order to Identify New Potential Treatment Avenues.NCT05720676 · collaborator · 2023-03-01
UNKNOWNSponsor roles
lead sponsor54
collaborator12
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.